| 3 | 0 | 10 |
| 下载次数 | 被引频次 | 阅读次数 |
腱鞘巨细胞瘤（TGCT）是一种罕见的间叶源性肿瘤，好发于关节、腱鞘及滑囊，包括结节型TGCT(N-TGCT)和弥漫型TGCT(D-TGCT)。与N-TGCT相比，D-TGCT的局部侵袭性更强。TGCT的传统治疗方法是手术切除，但术后常出现局部复发，反复多次复发会影响患者生活质量，严重者甚至危及患者生命。随着骨与软组织肿瘤治疗理念的更新、技术的进步、多学科综合治疗的日益完善，尤其是集落刺激因子1受体（CSF1R）抑制剂的问世和临床应用，TGCT患者的预后有望得到明显改善。中华医学会骨科学分会骨肿瘤学组联合中国临床肿瘤学会肉瘤专家委员会组织相关专家制定《中国腱鞘巨细胞瘤临床诊疗专家共识》，规范化TGCT的临床诊疗实践，以改善TGCT患者的预后。
Abstract：Tenosynovial giant cell tumor(TGCT) is a rare mesenchymal tumor that commonly arises in joints, tendon sheaths, and bursae. It comprises the nodular type(N-TGCT) and the diffuse type(D-TGCT). Compared with N-TGCT, D-TGCT exhibits stronger local aggressiveness. Surgical resection is the traditional treatment for TGCT; however, postoperative local recurrence is common. Repeated recurrences can affect patients' quality of life and, in severe cases, even pose a life-threatening risk. With the evolution of treatment concepts, advances in technology, and the growing adoption of multidisciplinary comprehensive treatment for bone and soft tissue tumors, particularly the introduction and clinical application of colony-stimulating factor 1 receptor(CSF1R) inhibitors, the prognosis of TGCT patients is anticipated to markedly improve in light of these developments. The Bone Oncology Group of the Orthopaedic Branch of the Chinese Medical Association and the Sarcoma Expert Committee of the Chinese Society of Clinical Oncology have jointly formulated the Chinese Expert Consensus on the Clinical Diagnosis and Treatment of Tenosynovial Giant Cell Tumor, aiming to standardize clinical practices and improve patient outcomes.
[1] West RB, Rubin BP, Miller MA, et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells[J].Proc Natl Acad Sci U S A, 2006, 103(3):690-695.
[2] Mastboom MJL, Verspoor FGM, Verschoor AJ, et al.Higher incidence rates than previously known in tenosynovial giant cell tumors[J]. Acta Orthop, 2017, 88(6):688-694.
[3] Stacchiotti S, Durr HR, Schaefer IM, et al. Best clinical management of tenosynovial giant cell tumour(TGCT):A consensus paper from the community of experts[J]. Cancer Treat Rev, 2023, 112:102491.
[4] Urakawa H, Imagama S. Vimseltinib for tenosynovial giant cell tumour[J]. Lancet, 2024, 403(10445):2665-2667.
[5] Spierenburg G, van der Heijden L, van Langevelde K, et al.Tenosynovial giant cell tumors(TGCT):molecular biology,drug targets and non-surgical pharmacological approaches[J]. Expert Opin Ther Targets, 2022, 26(4):333-345.
[6] Spierenburg G, Grimison P, Chevreau C, et al. Long-term follow-up of nilotinib in patients with advanced tenosynovial giant cell tumours:long-term follow-up of nilotinib in TGCT[J]. Eur J Cancer, 2022, 173:219-228.
[7] Lipplaa A, Meijer D, van de Sande MAJ, et al. A novel colony-stimulating factor 1(CSF1)translocation involving human endogenous retroviral element in a tenosynovial giant cell tumor[J]. Genes Chromosomes Cancer, 2023, 62(4):223-230.
[8] van IDGP, Matusiak M, Charville GW, et al. Interactions in CSF1-driven tenosynovial giant cell tumors[J]. Clin Cancer Res, 2022, 28(22):4934-4946.
[9] Ho J, Peters T, Dickson BC, et al. Detection of CSF1 rearrangements deleting the 3'UTR in tenosynovial giant cell tumors[J]. Genes Chromosomes Cancer, 2020, 59(2):96-105.
[10] Ottaviani S, Ayral X, Dougados M, et al. Pigmented villonodular synovitis:a retrospective single-center study of 122cases and review of the literature[J]. Semin Arthritis Rheum, 2011, 40(6):539-546.
[11] Siegel M, Bode L, Sudkamp N, et al. Treatment, recurrence rates and follow-up of tenosynovial giant cell tumor(TGCT)of the foot and ankle-a systematic review and meta-analysis[J]. PLoS One, 2021, 16(12):e0260795.
[12] Xie GP, Jiang N, Liang CX, et al. Pigmented villonodular synovitis:a retrospective multicenter study of 237 cases[J].PLoS One, 2015, 10(3):e0121451.
[13] Kong W, Shi Y, Zhao X, et al. Advancing preoperative diagnosis:case report and imaging analysis of cervical spine tenosynovial giant cell tumor[J]. Am J Case Rep, 2025, 26:e946427.
[14] Yang X, Yao L, Yu T, et al. Case report:extra-articular diffuse tenosynovial giant cell tumor of the temporomandibular joint[J]. Front Oncol, 2021, 11:643635.
[15] AlHarbi K, AlHussain S. Recurrent diffuse tenosynovial giant cell tumor of the posterior knee:a rare presentation with synovial herniation(Baker's cyst)in a young patient[J]. BMC Musculoskelet Disord, 2025, 26(1):281.
[16] Gouin F, Noailles T. Localized and diffuse forms of tenosynovial giant cell tumor(formerly giant cell tumor of the tendon sheath and pigmented villonodular synovitis)[J]. Orthop Traumatol Surg Res, 2017, 103(1S):S91-S97.
[17] Kager M, Kager R, Falek P, et al. Tenosynovial giant cell tumor[J]. Folia Med Cracov, 2022, 62(2):93-107.
[18] Spierenburg G, Suevos Ballesteros C, Stoel BC, et al. MRI of diffuse-type tenosynovial giant cell tumour in the knee:a guide for diagnosis and treatment response assessment[J].Insights Imaging, 2023, 14(1):22.
[19] Schenk P, Schoni M, Urbanschitz L, et al. Tenosynovial giant cell tumor(TSGCT)of the hip:MRI accuracy and results of surgical treatment[J]. Acta Orthop Belg, 2023, 89(1):65-69.
[20] Wang C, Song RR, Kuang PD, et al. Giant cell tumor of the tendon sheath:magnetic resonance imaging findings in 38patients[J]. Oncol Lett, 2017, 13(6):4459-4462.
[21] Choi WS, Lee SK, Kim JY, et al. Diffuse-type tenosynovial giant cell tumor:what are the important findings on the initial and follow-up MRI?[J]. Cancers(Basel), 2024, 16(2).
[22] Kim JH, Lee SK, Kim JY. Prediction of local recurrence in tenosynovial giant cell tumor of the knee:based on preoperative MRI evaluation into disease subtypes and severity[J]. PLoS One, 2023, 18(6):e0287028.
[23] Mastboom MJL, Lips W, van Langevelde K, et al. The effect of imatinib mesylate in diffuse-type tenosynovial giant cell tumours on MR imaging and PET-CT[J]. Surg Oncol,2020, 35:261-267.
[24] Wang Y, Tang J, Luo Y. The value of sonography in diagnosing giant cell tumors of the tendon sheath[J]. J Ultrasound Med, 2007, 26(10):1333-1340.
[25] Middleton WD, Patel V, Teefey SA, et al. Giant cell tumors of the tendon sheath:analysis of sonographic findings[J].AJR Am J Roentgenol, 2004, 183(2):337-339.
[26] Murphey MD, Rhee JH, Lewis RB, et al. Pigmented villonodular synovitis:radiologic-pathologic correlation[J]. Radiographics, 2008, 28(5):1493-1518.
[27] Sbaraglia M, Gambarotti M, Businello G, et al. Intraarticular tumors[J]. Surg Pathol Clin, 2021, 14(4):665-677.
[28] Somerhausen NS, Fletcher CD. Diffuse-type giant cell tumor:clinicopathologic and immunohistochemical analysis of 50 cases with extraarticular disease[J]. Am J Surg Pathol, 2000, 24(4):479-492.
[29] Cupp JS, Miller MA, Montgomery KD, et al. Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides[J]. Am J Surg Pathol, 2007, 31(6):970-976.
[30] Tsuda Y, Hirata M, Katayama K, et al. Massively parallel sequencing of tenosynovial giant cell tumors reveals novel CSF1 fusion transcripts and novel somatic CBL mutations[J]. Int J Cancer, 2019, 145(12):3276-3284.
[31] Mejbel H, Siegal GP, Wei S. Intramuscular tenosynovial giant cell tumor harboring a novel CSF1-CD96 fusion transcript[J]. Int J Surg Pathol, 2022, 30(3):335-338.
[32] van der Heijden L, Spierenburg G, Kendal JK, et al. Multimodal management of tenosynovial giant cell tumors(TGCT)in the landscape of new druggable targets[J]. J Surg Oncol, 2023, 128(3):478-488.
[33] Vougiouklakis T, Shen G, Feng X, et al. Molecular profiling of atypical tenosynovial giant cell tumors reveals novel non-CSF1 fusions[J]. Cancers(Basel), 2019, 12(1).
[34] Byers PD, Cotton RE, Deacon OW, et al. The diagnosis and treatment of pigmented villonodular synovitis[J]. J Bone Joint Surg Br, 1968, 50(2):290-305.
[35] Ogilvie-Harris DJ, McLean J, Zarnett ME. Pigmented villonodular synovitis of the knee. The results of total arthroscopic synovectomy, partial, arthroscopic synovectomy,and arthroscopic local excision[J]. J Bone Joint Surg Am,1992, 74(1):119-123.
[36] Palmerini E, Staals EL, Maki RG, et al. Tenosynovial giant cell tumour/pigmented villonodular synovitis:outcome of294 patients before the era of kinase inhibitors[J]. Eur J Cancer, 2015, 51(2):210-217.
[37] Spierenburg G, Staals EL, Palmerini E, et al. Active surveillance of diffuse-type tenosynovial giant cell tumors:a retrospective, multicenter cohort study[J]. Eur J Surg Oncol,2024, 50(2):107953.
[38] Stacchiotti S, Dürr HR, Schaefer IM, et al. Best clinical management of tenosynovial giant cell tumour(TGCT):A consensus paper from the community of experts[J]. Cancer Treatment Reviews, 2023:112.
[39] Verspoor FGM, Mastboom MJL, Hannink G, et al. The effect of surgery in tenosynovial giant cell tumours as measured by patient-reported outcomes on quality of life and joint function[J]. Bone Joint J, 2019, 101-B(3):272-280.
[40] Ozben H, Coskun T. Giant cell tumor of tendon sheath in the hand:analysis of risk factors for recurrence in 50 cases[J]. BMC Musculoskelet Disord, 2019, 20(1):457.
[41] Mastboom MJL, Staals EL, Verspoor FGM, et al. Surgical treatment of localized-type tenosynovial giant cell tumors of large joints:a study based on a multicenter-pooled database of 31 international sarcoma centers[J]. J Bone Joint Surg Am, 2019, 101(14):1309-1318.
[42] Mastboom MJL, Palmerini E, Verspoor FGM, et al. Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours:an international, retrospective, cohort study[J]. Lancet Oncol, 2019, 20(6):877-886.
[43] Mollon B, Griffin AM, Ferguson PC, et al. Combined arthroscopic and open synovectomy for diffuse pigmented villonodular synovitis of the knee[J]. Knee Surg Sports Traumatol Arthrosc, 2016, 24(1):260-266.
[44] Chandra AA, Agarwal S, Donahue A, et al. Arthroscopic versus open management of diffuse-type tenosynovial giant cell tumor of the knee:a meta-analysis of retrospective cohort studies[J]. J Am Acad Orthop Surg Glob Res Rev,2021, 4(12).
[45] Yao L, Li Y, Li T, et al. What are the recurrence rates, complications, and functional outcomes after multiportal arthroscopic synovectomy for patients with knee diffuse-type tenosynovial giant-cell tumors?[J]. Clin Orthop Relat Res,2024, 482(7):1218-1229.
[46] Tibbo ME, Wyles CC, Rose PS, et al. Long-term outcome of hip arthroplasty in the setting of pigmented villonodular synovitis[J]. J Arthroplasty, 2018, 33(5):1467-1471.
[47] Li T, Mei L, Xu Y, et al. Total hip arthroplasty or arthroscopy for pigmented villonodular synovitis of the hip:a retrospective study with 3-year follow-up at minimum[J]. Orthop Surg, 2023, 15(6):1498-1504.
[48] Korim MT, Clarke DR, Allen PE, et al. Clinical and oncological outcomes after surgical excision of pigmented villonodular synovitis at the foot and ankle[J]. Foot Ankle Surg,2014, 20(2):130-134.
[49] Houdek MT, Scorianz M, Wyles CC, et al. Long-term outcome of knee arthroplasty in the setting of pigmented villonodular synovitis[J]. Knee, 2017, 24(4):851-855.
[50] Panciera A, Colangelo A, Di Martino A, et al. Total knee arthroplasty in pigmented villonodular synovitis osteoarthritis:a systematic review of literature[J]. Musculoskelet Surg, 2024, 108(2):145-152.
[51] Ono Y, Miyakoshi N, Tsuchie H, et al. Pigmented villonodular synovitis around the elbow joint that required upper arm amputation[J]. J Med Cases, 2020, 11(7):201-203.
[52] Chien JC, Wei YP, Chen CY, et al. Long-term functional outcomes of diffuse pigmented villonodular synovitis of knee:the role of adjuvant radiotherapy[J]. Medicine(Baltimore), 2021, 100(12):e23794.
[53] Park G, Kim YS, Kim JH, et al. Low-dose external beam radiotherapy as a postoperative treatment for patients with diffuse pigmented villonodular synovitis of the knee:4 recurrences in 23 patients followed for mean 9 years[J]. Acta Orthop, 2012, 83(3):256-260.
[54] Tie K, Wang H, Chen B, et al. Midterm outcomes of 18 patients with primary intra-articular diffuse tenosynovial giant cell tumor(TGCT)of the knee treated with complete arthroscopic synovectomy and postoperative low-dose radiotherapy at a mean follow-up of 68 months[J]. Arch Orthop Trauma Surg, 2023, 143(4):2121-2127.
[55] Blanco CE, Leon HO, Guthrie TB. Combined partial arthroscopic synovectomy and radiation therapy for diffuse pigmented villonodular synovitis of the knee[J]. Arthroscopy, 2001, 17(5):527-531.
[56] Horoschak M, Tran PT, Bachireddy P, et al. External beam radiation therapy enhances local control in pigmented villonodular synovitis[J]. Int J Radiat Oncol Biol Phys, 2009, 75(1):183-187.
[57] de Carvalho LH, Soares LF, Goncalves MB, et al. Longterm success in the treatment of diffuse pigmented villonodular synovitis of the knee with subtotal synovectomy and radiotherapy[J]. Arthroscopy, 2012, 28(9):1271-1274.
[58] Griffin AM, Ferguson PC, Catton CN, et al. Long-term outcome of the treatment of high-risk tenosynovial giant cell tumor/pigmented villonodular synovitis with radiotherapy and surgery[J]. Cancer, 2012, 118(19):4901-4909.
[59] Baniel C, Yoo CH, Jiang A, et al. Long-term outcomes of diffuse or recurrent tenosynovial giant cell tumor treated with postoperative external beam radiation therapy[J]. Pract Radiat Oncol, 2023, 13(3):e301-e307.
[60] Tap WD, Gelderblom H, Palmerini E, et al. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour(ENLIVEN):a randomised phase 3 trial[J]. Lancet, 2019,394(10197):478-487.
[61] Niu X, Ravi V, Shan B, et al. MANEUVER:a phaseⅢstudy of pimicotinib to assess efficacy and safety in tenosynovial giant cell tumor patients[J]. Future Oncol, 2024, 17:1-8.
[62] Gelderblom H, Bhadri V, Stacchiotti S, et al. Vimseltinib versus placebo for tenosynovial giant cell tumour(MOTION):a multicentre, randomised, double-blind,placebo-controlled, phase 3 trial[J]. Lancet, 2024, 403(10445):2709-2719.
[63] Verspoor FGM, Mastboom MJL, Hannink G, et al. Longterm efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor[J]. Sci Rep, 2019, 9(1):14551.
[64] Gelderblom H, Cropet C, Chevreau C, et al. Nilotinib in locally advanced pigmented villonodular synovitis:a multicentre, open-label, single-arm, phase 2 trial[J]. Lancet Oncol, 2018, 19(5):639-648.
[65] Cassier PA, Italiano A, Gomez-Roca CA, et al. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue:a doseescalation and dose-expansion phase 1 study[J]. Lancet Oncol, 2015, 16(8):949-956.
[66] Cassier PA, Italiano A, Gomez-Roca C, et al. Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour[J]. Eur J Cancer, 2020, 141:162-170.
[67] Soucie JM, Wang C, Forsyth A, et al. Range of motion measurements:reference values and a database for comparison studies[J]. Haemophilia, 2011, 17(3):500-507.
[68] Gelhorn HL, Ye X, Speck RM, et al. The measurement of physical functioning among patients with tenosynovial giant cell tumor(TGCT)using the patient-reported outcomes measurement information system(PROMIS)[J]. J Patient Rep Outcomes, 2019, 3(1):6.
[69] Palmerini E, Healey JH, Bernthal NM, et al. Tenosynovial giant cell tumor observational platform project(TOPP)registry:a 2-year analysis of patient-reported outcomes and treatment strategies[J]. Oncologist, 2023, 28(6):e425-e435.
[70] Gelhorn HL, Tong S, McQuarrie K, et al. Patient-reported symptoms of tenosynovial giant cell tumors[J]. Clin Ther,2016, 38(4):778-793.
[71] Peterfy C, Chen Y, Countryman P, et al. CSF1 receptor inhibition of tenosynovial giant cell tumor using novel diseasespecific MRI measures of tumor burden[J]. Future Oncol,2022, 18(12):1449-1459.
基本信息:
DOI：
中图分类号:R738
引用信息:
[1]中华医学会骨科学分会骨肿瘤学组 ,中国临床肿瘤学会肉瘤专家委员会 ,吴朝阳等.中国腱鞘巨细胞瘤临床诊疗专家共识[J].中华骨与关节外科杂志,2025,18(09):769-780.
基金信息: